|
A Look Inside Preclinical Research Using PET, SPECT, And CT
By Mark Lane, Manager, Discovery Operations/Principal Investigator, Molecular Imaging and Dustin Kentala, Associate Research Scientist, Molecular Imaging, MPI Research
With a recent shift in established paradigms within drug development, the need for molecular imaging platforms is increasing. By utilizing multidisciplinary fields such as synthetic chemistry, pharmacology, and molecular biology, it is possible to capture images in vivo by monitoring novel, customized, and commercially available imaging probes. This article highlights the imaging uses of single photon emission computed tomography (SPECT) and positron emission tomography (PET).
|
|
What Does Vertex Look For When Selecting A CRO?
By Rob Wright, Chief Editor, Life Science Leader magazine
Peter A. DiBiaso is the head of clinical business operations for Vertex Pharmaceuticals and responsible for the leadership of clinical business operations in support of Vertex’s global development portfolio. In this Q&A, he shares insights about the growing trend of strategic partnering between sponsors and CROs.
|
